Andere talen Arcellx, Inc.

Aandelen

ACLX

US03940C1009

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
52,82 ^USD	-2,89%		-1,36%	-4,83%

18/04	Arcellx Insider verkocht aandelen ter waarde van $522.260, volgens een recente SEC filing	MT
03/04	Arcellx Insider verkocht aandelen ter waarde van $1.548.887, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing	18/04
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04/04
Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing	03/04
Arcellx Insider Sold Shares Worth $35,575,755, According to a Recent SEC Filing	25/03
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	20/03
Arcellx Insider Sold Shares Worth $633,582, According to a Recent SEC Filing	19/03
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference	29/02
Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Earnings Flash (ACLX) ARCELLX Posts Q4 Revenue $63.1M	28/02
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights	28/02
Arcellx, Inc. Enters an Assignment of Lease with A Third Party Sublessee	31/01
Arcellx, Inc. Approves Relocation of the Headquarters	31/01
Arcellx Insider Sold Shares Worth $419,926, According to a Recent SEC Filing	08/01
Arcellx Insider Sold Shares Worth $1,606,804, According to a Recent SEC Filing	08/01
Arcellx Insider Sold Shares Worth $470,551, According to a Recent SEC Filing	08/01
Arcellx Insider Sold Shares Worth $6,020,281, According to a Recent SEC Filing	19/12
Arcellx Insider Sold Shares Worth $24,774,441, According to a Recent SEC Filing	18/12
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH	11/12
Arcellx Phase 1 Expansion Study Data for Cancer Candidate Shows 100% Overall Response Rate	08/12
Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash	08/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arcellx, Inc.

Aandelen

ACLX

US03940C1009

Andere talen

Filters